Phase IV clinical study on the safety and effectiveness of Sanqi Longxuejie Capsules in the treatment of coronary heart disease with stable exertional angina pectoris (Grade I, II)

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100053707

Enrollment

Unknown

Registered

2021-11-27

Start date

2021-11-24

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease with stable exertional angina pectoris (Grade I, II)

Interventions

Experimental group:Sanqi Longxuejie Capsules,2 capsules/time, 3 times/day

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Adult patients aged 18 to 75 years, regardless of gender; 2. Meet the diagnostic criteria of Western medicine for stable exertional angina pectoris (refer to the 2018 Guidelines for the Diagnosis and Treatment of Stable Coronary Heart Disease); 3. Angina pectoris is graded into grades I and II; 4. The TCM syndrome type conforms to the syndrome of blood stasis obstruction; 5. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with acute coronary syndrome, severe myocarditis, severe arrhythmia, severe cardiac insufficiency (class IV cardiac function or left ventricular ejection fraction (LVEF) = 180mmHg or diastolic blood pressure >= 110mmHg); 3. Those with active bleeding or high risk of bleeding (such as those who have been diagnosed with peptic ulcer within the past 3 months); 4. Combined with severe liver and kidney function damage (ALT, AST or total bilirubin > 2 times the upper limit of the normal reference value, or Scr > 1.5 times the upper limit of the normal reference value), combined with serious primary diseases such as hematopoietic system, malignant tumor, mental illness By; 5. Pregnant, planning pregnancy or lactating women; 6. Those who have participated in other clinical trials within the past 3 months; 7. Those who are allergic to the test drug or its ingredients; 8. The researchers believe that patients who are not suitable to participate in this clinical trial and patients who do not cooperate or have poor compliance due to other reasons.

Design outcomes

Primary

Measure	Time frame
Seattle Angina Questionnaire;	—

Secondary

Measure	Time frame
Traditional Chinese Medicine Syndrome Score of Heart Blood Stasis Syndrome;quality of life scale score;Withdrawal rate and usage of nitroglycerin;	—

Countries

China

Contacts

Public ContactShi Dazhuo

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences

shidazhuo@126.com+86 13911972856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026